Resources Repository
-
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Preferences/Values | Technology Assessment | Health Outcomes | Health/Medicine | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Science/Technology | North America | Europe -
GuidelinesPublication 2012Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Task Force-1
This paper provides an overview of the work of the joint Task Force between the …
This paper provides an overview of the work of the joint Task Force between the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM), provides the overarching recommendations, and discusses future work that is needed. The audience for these papers includes anyone who build models, stakeholders who utilize their results, and those concerned with the use of models to support decision making. This article is part 1 of…
Dynamic Simulation | Calibration/Validation | Health Outcomes | Health/Medicine | Costing Methods | Value of Information | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Decision Analysis | Infectious Diseases -
ReviewPublication 2023Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: ISPOR Special Interest Group Report
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes …
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes potential approaches to mitigate them. A multidisciplinary team of biosimilar experts conducted a systematic review of literature and engaged in review rounds to identify these challenges. The article suggests that health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and conduct price comparisons for biosimilars reimbursed for the same indication as the reference biologic. In cases…
Preferences/Values | Technology Assessment | Health/Medicine | Evidence Synthesis | Policy/Regulation -
Working PaperPublication 2018Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis
Increasing life expectancy is a major goal of many policies implemented around the world. As …
Increasing life expectancy is a major goal of many policies implemented around the world. As a result, the value of reducing mortality risk has been extensively studied and several organizations have developed recommendations for estimating these values in benefit-cost analysis. However, both the recommendations and the underlying research primarily address high-income settings, raising questions about the extent to which the results are applicable in low- and middle-income countries. The recommendations are also diverse, reflecting differing…
Preferences/Values | Health Outcomes | Health/Medicine | Priority Setting/Ethics | Decision Analysis | Benefit-Cost Analysis | Social Determinants | Policy/Regulation | Economics/Finance | Global -
Working PaperPublication 2018Valuing Nonfatal Health Risk Reductions
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- …
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- and middle-income countries. The approach for valuation ideally would be based on estimates of individuals’ willingness to pay for changes in their own risks. However, high quality valuation research is not available for many nonfatal conditions even in high-income settings. Typically, two approaches are used either alone or in combination as rough proxies. The first involves applying an estimate of…
Preferences/Values | Health Outcomes | Health/Medicine | Priority Setting/Ethics | Decision Analysis | Benefit-Cost Analysis | Social Determinants | Policy/Regulation | Economics/Finance | Global | Critical Thinking/Analysis -
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Preferences/Values | Health Outcomes | Health/Medicine | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance | North America | Europe -
ReviewPublication 2017Quality of Life as an Outcome of Opioid Use Disorder Treatment
The recent opioid epidemic has prompted renewed interest in opioid use disorder treatment, but there …
The recent opioid epidemic has prompted renewed interest in opioid use disorder treatment, but there is little evidence regarding health-related quality-of-life (HRQoL) outcomes in treatment programs. Measuring HRQoL represents an opportunity to consider outcomes of opioid use disorder treatment that are more patient-centered and more relevant to overall health than abstinence alone. This systematic literature review explores the extent to which the collection of HRQoL by opioid treatment programs is documented in the treatment program literature.…
Preferences/Values | Health Outcomes | Health/Medicine | Evidence Synthesis | Chronic Disease/Risk | Mental Health | Social Determinants | Health Systems | Economics/Finance -
ReviewPublication 2015Agent-Based Models and Microsimulation
This article reviews the principles and applications of agent-based models (ABMs). ABMs are computational models …
This article reviews the principles and applications of agent-based models (ABMs). ABMs are computational models used to simulate the actions and interactions of “agents” within a system. Usually, each agent has a set of rules for how he or she responds to the environment and to other agents. These models are used to gain insight into the emergent behavior of complex systems with many agents, in which the emergent behavior depends upon the micro-level behavior…
Dynamic Simulation | Energy/Engineering | Health/Medicine | Mathematical Models | State-Transition | Microsimulation | Military/Defense | Science/Technology -
GuidelinesPublication 2012Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Task Force-7
This paper discusses how to improve trust in the use of health care models through …
This paper discusses how to improve trust in the use of health care models through validation and transparency. Validation involves face validity (wherein experts evaluate model structure, data sources, assumptions, and results), verification or internal validity (check accuracy of coding), cross validity (comparison of results with other models analyzing same problem), external validity (comparing model results to real-world results), and predictive validity (comparing model results with prospectively observed events). Recommendations are provided for nontechnical description…
Calibration/Validation | Health Outcomes | Health/Medicine | Costing Methods | Mathematical Models